BioMérieux: Invest Securities raises TP

(CercleFinance.com) - Invest Securities reiterates its 'buy' rating on bioMérieux shares, with a target price raised from E123 to E126, believing that it continues to stand out from competition, with a robust outlook and valuation levels that are still relatively low.


The broker highlights an "exemplary" Q2 publication, above expectations, thanks to a further outperformance by the MDx division and surprising momentum in microbiology, as well as an increase in 2024 targets.

With the exception of a higher WCR due to product launches, all the indicators are in the green, with a dynamic H1 that lends further credibility to the objectives set in the GO28 plan, with which we are in line, it continues.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.